<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02284607</url>
  </required_header>
  <id_info>
    <org_study_id>GV29609</org_study_id>
    <nct_id>NCT02284607</nct_id>
  </id_info>
  <brief_title>A Study of High Dose MHAA4549A in Healthy Volunteers</brief_title>
  <official_title>A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF HIGH DOSE MHAA4549A IN HEALTHY VOLUNTEERS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This Phase 1, randomized, double-blind, placebo-controlled study will evaluate the safety,&#xD;
      tolerability and pharmacokinetics of two, single intravenous (IV) high doses of MHAA4549A as&#xD;
      compared to placebo when administered to healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 3, 2014</start_date>
  <completion_date type="Actual">March 13, 2015</completion_date>
  <primary_completion_date type="Actual">March 13, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and nature of adverse events (AEs)</measure>
    <time_frame>Until study discontinuation/termination, up to 120 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in vital signs during and following MHAA4549A administration</measure>
    <time_frame>From baseline to end of study, up to 120 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in ECG findings during and following MHAA4549A administration</measure>
    <time_frame>From baseline to end of study, up to 120 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of AEs</measure>
    <time_frame>Until study discontinuation/termination, up to 120 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (composite outcome measure): parameters derived from the nasal and serum concentration-time profile of MHAA4549A (area under the concentration-time curve [AUC], Cmax, tmax, clearance, Vss, half-life (t1/2), mean residence time)</measure>
    <time_frame>Up to 120 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>MHAA4549A higher dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MHAA4549A lower dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MHAA4549A</intervention_name>
    <description>MHAA4549A single, intravenous dose administration, lower dose level</description>
    <arm_group_label>MHAA4549A lower dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MHAA4549A</intervention_name>
    <description>MHAA4549A single, intravenous dose administration, higher dose level</description>
    <arm_group_label>MHAA4549A higher dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo to MHAA4549A administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years and older&#xD;
&#xD;
          -  Body mass index (BMI) between 18 and 32 kg/m2, inclusive&#xD;
&#xD;
          -  Weight 40 - 100 kg&#xD;
&#xD;
          -  In good health, determined by no clinically significant findings from medical history,&#xD;
             12-lead ECG, vital signs, and clinical laboratory evaluations&#xD;
&#xD;
          -  Willing to use acceptable contraceptive measures as defined by the protocol&#xD;
&#xD;
          -  Agreeable to, and deemed able to by the investigator, to comply with the requirements&#xD;
             of the study, including the follow-up period&#xD;
&#xD;
          -  Willing to abstain from the use of drugs of abuse while enrolled in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or clinically significant manifestations of disorders&#xD;
&#xD;
          -  History of acute allergic reaction or drug allergies&#xD;
&#xD;
          -  History or presence of an abnormal ECG&#xD;
&#xD;
          -  History of significant alcohol abuse within 1 year prior to screening or regular use&#xD;
             of alcohol within 6 months prior to the screening visit&#xD;
&#xD;
          -  History of significant drug abuse within 1 year prior to screening&#xD;
&#xD;
          -  Current tobacco smokers&#xD;
&#xD;
          -  Positive drug screen at screening or at check-in&#xD;
&#xD;
          -  Positive pregnancy test result at screening or Day -1 or breast feeding during the&#xD;
             study&#xD;
&#xD;
          -  Males who have a pregnant female partner&#xD;
&#xD;
          -  Donation of plasma within 7 days prior to study drug administration&#xD;
&#xD;
          -  Donation or loss of whole blood&#xD;
&#xD;
          -  Receipt of blood products within 2 months before initiation of dosing on Day 1&#xD;
&#xD;
          -  History of malignancy within 10 years of screening except completely excised basal&#xD;
             cell carcinoma or squamous cell carcinoma of the skin&#xD;
&#xD;
          -  History of severe systemic bacterial, fungal, or parasitic infections associated with&#xD;
             more than two hospitalizations per year or more than two courses of intravenous (IV)&#xD;
             antibiotics within 1 year&#xD;
&#xD;
          -  Received oral antibiotics within 4 weeks before initiation of dosing on Day 1, or IV&#xD;
             antibiotics within 8 weeks before initiation of dosing&#xD;
&#xD;
          -  Hospitalization within 4 weeks before initiation of dosing on Day 1&#xD;
&#xD;
          -  Use of any over the counter or prescription medications/products within 7 days prior&#xD;
             to Day 1 and unwilling to abstain from the use of such drugs up until at least the Day&#xD;
             29 study visit, unless deemed acceptable by the investigator and Sponsor&#xD;
&#xD;
          -  Participation in a clinical trial within 4 weeks&#xD;
&#xD;
          -  Received any vaccine within 14 days prior to screening&#xD;
&#xD;
          -  Positive blood test for chronic viral infections&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>inVentiv Health Clinique</name>
      <address>
        <city>Quebec</city>
        <zip>G1P 0A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>October 31, 2014</study_first_submitted>
  <study_first_submitted_qc>November 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2014</study_first_posted>
  <last_update_submitted>March 7, 2017</last_update_submitted>
  <last_update_submitted_qc>March 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

